CA2598080A1 - Peptides fixant les amyloides, produits analogues et applications de ces peptides - Google Patents
Peptides fixant les amyloides, produits analogues et applications de ces peptides Download PDFInfo
- Publication number
- CA2598080A1 CA2598080A1 CA002598080A CA2598080A CA2598080A1 CA 2598080 A1 CA2598080 A1 CA 2598080A1 CA 002598080 A CA002598080 A CA 002598080A CA 2598080 A CA2598080 A CA 2598080A CA 2598080 A1 CA2598080 A1 CA 2598080A1
- Authority
- CA
- Canada
- Prior art keywords
- chg
- mleu
- amyloid
- group
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0503434.3 | 2005-02-18 | ||
GBGB0503434.3A GB0503434D0 (en) | 2005-02-18 | 2005-02-18 | Amyloid-binding peptides, analogues and uses thereof |
PCT/GB2006/000539 WO2006087550A2 (fr) | 2005-02-18 | 2006-02-16 | Peptides fixant les amyloides, produits analogues et applications de ces peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2598080A1 true CA2598080A1 (fr) | 2006-08-24 |
Family
ID=34400981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002598080A Abandoned CA2598080A1 (fr) | 2005-02-18 | 2006-02-16 | Peptides fixant les amyloides, produits analogues et applications de ces peptides |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1853626A2 (fr) |
JP (1) | JP2008530194A (fr) |
AU (1) | AU2006215406A1 (fr) |
CA (1) | CA2598080A1 (fr) |
GB (1) | GB0503434D0 (fr) |
WO (1) | WO2006087550A2 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
JP5209477B2 (ja) | 2005-09-09 | 2013-06-12 | ノバルティス アーゲー | プリオンに特異的なペプトイド試薬 |
PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
KR101667623B1 (ko) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
JP4777225B2 (ja) * | 2006-12-04 | 2011-09-21 | キヤノン株式会社 | 吐出用液体及び吐出方法 |
EP2124952A2 (fr) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Méthode de traitement d'amyloïdoses |
WO2009061744A2 (fr) * | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | Dérivés de 4-(p-quinolyl)-2-hydroxybutanamide pour le traitement de maladies mitochondriales |
JP5554528B2 (ja) * | 2009-09-08 | 2014-07-23 | 国立大学法人 岡山大学 | 新規アミロイドβ凝集体結合性ペプチドおよび新規アミロイドβ凝集体結合性ペプチドを用いたアミロイド病の検査方法 |
MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
WO2013082045A1 (fr) * | 2011-11-28 | 2013-06-06 | Buck Institute For Age Research | Mimétiques peptidiques à boucle de nétrine et utilisations de ceux-ci |
HU231182B1 (hu) * | 2013-05-17 | 2021-08-30 | Szegedi Tudományegyetem | A ß-amiloid toxicitását gátló kis peptid inhibitorok |
JP6660877B2 (ja) * | 2013-09-26 | 2020-03-11 | フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | アミロイド−β−結合性ペプチド、ならびにアルツハイマー型認知症の治療および診断のためのその使用 |
KR102248804B1 (ko) * | 2014-03-12 | 2021-05-11 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
CN106800590B (zh) | 2015-11-25 | 2021-04-09 | 杭州智鹤丹谷生物医药有限公司 | 一种结合多种淀粉样蛋白单体和聚集体的多肽及其应用 |
US11970521B2 (en) * | 2016-08-20 | 2024-04-30 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Neuroprotective beta amyloid core peptides and peptidomimetic derivatives |
KR101956302B1 (ko) * | 2016-11-30 | 2019-03-11 | 연세대학교 산학협력단 | 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303567B1 (en) * | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
AU781292B2 (en) * | 1999-03-04 | 2005-05-12 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation comprising D-amino acids |
-
2005
- 2005-02-18 GB GBGB0503434.3A patent/GB0503434D0/en not_active Ceased
-
2006
- 2006-02-16 WO PCT/GB2006/000539 patent/WO2006087550A2/fr not_active Application Discontinuation
- 2006-02-16 CA CA002598080A patent/CA2598080A1/fr not_active Abandoned
- 2006-02-16 EP EP06709776A patent/EP1853626A2/fr not_active Withdrawn
- 2006-02-16 AU AU2006215406A patent/AU2006215406A1/en not_active Abandoned
- 2006-02-16 JP JP2007555695A patent/JP2008530194A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2006087550A3 (fr) | 2007-05-24 |
WO2006087550A2 (fr) | 2006-08-24 |
AU2006215406A1 (en) | 2006-08-24 |
GB0503434D0 (en) | 2005-03-30 |
EP1853626A2 (fr) | 2007-11-14 |
WO2006087550A8 (fr) | 2006-12-14 |
JP2008530194A (ja) | 2008-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2598080A1 (fr) | Peptides fixant les amyloides, produits analogues et applications de ces peptides | |
Kapurniotu et al. | Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity | |
Matharu et al. | Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease | |
Gazit | Mechanistic studies of the process of amyloid fibrils formation by the use of peptide fragments and analogues: implications for the design of fibrillization inhibitors | |
Kaffy et al. | Designed glycopeptidomimetics disrupt protein–Protein interactions mediating amyloid β-peptide aggregation and restore neuroblastoma cell viability | |
US20240033318A1 (en) | Peptidyl inhibitors of calcineurin-nfat interaction | |
JP2011057685A (ja) | ニューロンの成長を調節する化合物およびそれらの使用 | |
Frydman-Marom et al. | Structural basis for inhibiting β-amyloid oligomerization by a non-coded β-breaker-substituted endomorphin analogue | |
CN111447941A (zh) | 用于细胞内递送装订肽的多肽缀合物 | |
EP1203019B1 (fr) | Peptides contenant l-amino acides n-substitues pour empecher l'association de brins beta | |
EP1204679B1 (fr) | Peptides contenant des acides d-amines n-substitues pour la prevention d'associations de brins-beta | |
US20230174582A1 (en) | Vipr2 antagonist peptide | |
Tanaka et al. | Design and synthesis of β-strand-fixed peptides inhibiting aggregation of amyloid β-protein | |
Haldar et al. | α-Aminoisobutyric acid modified protected analogues of β-amyloid residue 17–20: a change from sheet to helix | |
WO2024043249A1 (fr) | Peptide cyclique ou sel de celui-ci, et inhibiteur de mdmx | |
Singh et al. | Total Synthesis and Conformational Analysis of Naturally Occurring Lipovelutibols along with Lead Optimization of Lipovelutibol D | |
WO2014075137A1 (fr) | Peptides comprenant des lactames à substitution amino pour le traitement de la rétinopathie | |
Jain | Design and Synthesis of Beta-Hairpin Peptidomimetics for Modulating Integrin Mediated Cell Adhesion, Abeta Fibrillogenesis and p53-MDM2 Protein-Protein Interactions | |
SINOPOLI | International PhD in Translational Biomedicine XXVIII cycle | |
Bett | Amyloid Aggregation-Mitigating Peptides As Potential Alzheimer's Drugs | |
MXPA06002557A (es) | Compuestos que modulan el crecimiento neuronal y sus usos | |
Etienne | Incorporation of Cα, α-Disubstituted Amino Acids into Model Peptide Systems: Conformational Analysis and Possible Applications as Therapeutic Agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |